Latest Pyrazines Stories
ANN ARBOR, Mich., Jan.
Need the help of a pill to catch some zzzâ€™s? According to a new study youâ€™re not alone; the use of prescription sleep aids nearly tripled among young adults between 1998 and 2006.
SOUTH SAN FRANCISCO, Calif., Dec. 9 /PRNewswire/ -- Proteolix, Inc. today announced positive clinical data demonstrating that the company's lead product, carfilzomib, has single-agent activity and promotes durable responses in patients with relapsed and refractory multiple myeloma.
SAN FRANCISCO, Dec.
US-based pharmaceutical company Sepracor has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending to grant a marketing authorization for Lunivia brand eszopiclone in the EU for the treatment of insomnia.
U.S. drug regulators said they're reviewing labeling of Chantix after reports of traffic accidents and seizures involving users of the anti-smoking drug.
The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy, and support for myeloma patients, families, researchers, and physicians - today heralded the expansion of treatment options for previously untreated patients with multiple myeloma, giving patients in Canada and Europe access to drugs similar to what is available to patients in the United States.
Q. Last night, my boyfriend became so violent, I was afraid he was going to hit my 22-year-old daughter or me. He threatened to burn down our home, and he tried to kick me out. I just realized that he started changing in the past two weeks right after he started taking Chantix to quit smoking.
-- Elderly patients taking LUNESTA 2 mg showed significant improvements in measures of daytime function compared to placebo over a 12-week treatment period -- Elderly patients administered LUNESTA 2 mg showed no evidence of rebound insomnia and withdrawal symptoms were comparable to the placebo group upon discontinuation Sepracor Inc.
Sepracor Inc. (Nasdaq: SEPR) today announced the presentation of LUNESTA(R) brand eszopiclone Phase IV study data at the 21st European College of Neuropsychopharmacology (ECNP) Congress in Barcelona.